This article is more than 5 years old. Information may no longer be current.

Study shows fellow eye unaffected by anti-VEGF treatments for AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WAILEA, Hawaii — A protective effect was not observed for the fellow eye when unilateral neovascular age-related macular degeneration was treated with anti-VEGF agents, a retrospective study showed here.

The retrospective study looked at 445 patients from both the ANCHOR (Anti-VEGF antibody for the treatment of predominantly classic choroidal neovascularization in AMD) and MARINA (Minimally classic/occult trial of the anti-vascular endothelial growth factor antibody ranibizumab in the treatment of neovascular AMD) trials, according to K. Bailey Freund, MD. In data presented to the American Society of Retina Specialists, Dr. Freund said, in either study, no difference was found in conversion of the fellow eye from dry to wet AMD.

In the MARINA study, patients were randomly assigned to receive monthly injections of 0.3 mg or 0.5 mg ranibizumab or sham therapy. In the ANCHOR study, patients received ranibizumab or photodynamic therapy. Conversion rates were based on angiography and were calculated at 12 and 24 months of follow-up.

"Perhaps the sample size was inadequate to detect a small treatment effect," Dr. Freund said of the study's limitations.